A Tumor-Agnostic NTRK (TRK) Inhibitor.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30901551.
- Also identified by DOI 10.1016/j.cell.2019.02.049.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Larotrectinib is a small-molecule kinase inhibitor that targets NTRK fusions that occur in multiple types of cancer. Its FDA approval represents the first instance of a treatment indication being designated "tumor-agnostic" from the outset, being based on actionable genomic insights. To view this Bench to Bedside, open or download the PDF.
Medical subject headings
- Pyrazoles
- Pyrimidines
- Receptor Tyrosine Kinase-like Orphan Receptors